Asset profile
Liafensine
Small molecule
Evidence outlook · lead readout
NCT05113771 · Treatment Resistant Depression
The completed lead evidence has the design features that historically survive confirmatory trials — randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT05113771: The study randomized 197 participants to two liafensine doses or placebo, with participants and investigators blinded to treatment. Its primary clinical endpoint, change in MADRS score at Day 42 in DGM4-positive patients, favored combined liafensine over placebo with statistical significance, supporting a strong evidence grade.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.